---
schema_version: "secwatch.filing_event.v1"
accession: "0002019410-25-000020"
form_type: "8-K"
ticker: "CAI"
cik: "0002019410"
company_name: "Caris Life Sciences, Inc."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:26:17.888878+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Caris Life Sciences adopts 3% ownership threshold for derivative proceedings

## Summary
- Board approved amendment to bylaws on October 30, 2025 requiring 3% beneficial ownership to institute or maintain a derivative proceeding.
- Threshold applies to any shareholder or group of shareholders acting together under the Texas Business Organizations Code.
- Changes are effective immediately; full text of amended bylaws filed as Exhibit 3.1.

## SEC filing metadata
- accession: 0002019410-25-000020
- form_type: 8-K
- ticker: CAI
- cik: 0002019410
- company_name: Caris Life Sciences, Inc.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2019410/000201941025000020/0002019410-25-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2019410/000201941025000020/cai-20251030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002019410-25-000020
- JSON: https://secwatch.observer/filing/0002019410-25-000020.json
- Plain text: https://secwatch.observer/filing/0002019410-25-000020.txt

## Key facts
- Governance Changes
  Caris Life Sciences, Inc.: Amended bylaws to require a shareholder (or group of shareholders acting together) to beneficially own at least 3% of outstanding shares to institute or maintain a derivative proceeding (effective 2025-10-30).
  - Change: bylaw amendment
  - Effective: 2025-10-30
  source text: On October 30, 2025, the Board of Directors of Caris Life Sciences, Inc. (the “ Company ”) approved and adopted an amendment and restatement of the Company’s bylaws (the “ Bylaws ”) to provide that a shareholder (defined, in accordance with the Texas Business Organizations Code, to include a group of shareholders acting together) must beneficially own, at the time the derivative proceeding is instituted, a number of shares of common stock equal to at least three percent of the Company’s outstanding shares to institute or maintain a derivative proceeding.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2019410/000201941025000020/0002019410-25-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.